Skip to search formSkip to main contentSkip to account menu

evogliptin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
Renal fibrosis is considered to be the final common outcome of chronic kidney disease. Dipeptidyl peptidase-4 (DPP-4) inhibitors… 
2018
2018
Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice
2018
2018
Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
Background: Individualized treatment has already become a part of a routine clinical care. Many data on the effectiveness… 
2018
2018
The amelioration on the vascular inflammatory response by evogliptin, a novel dipeptidyl peptidase 4 inhibitor via regulation of SIRT1/NF-KAPPAB interaction
2017
2017
Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise
To evaluate the efficacy and safety of evogliptin, a newly developed dipeptidyl peptidase‐4 inhibitor, in patients with type 2… 
2017
2017
Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers
Evogliptin (DA‐1229), a novel dipeptidyl peptidase (DPP)‐4 inhibitor with high potency and selectivity, was approved in Korea for… 
2017
2017
In vitro evaluation of potential transporter‐mediated drug interactions of evogliptin
To date, little is known about the transporter-mediated drug-drug interaction (DDI) potential of evogliptin, a novel DPP-4… 
2017
2017
Pharmacokinetic comparison using two tablets of an evogliptin/metformin XR 2.5/500 mg fixed dose combination vs. 1 tablet each of evogliptin 5 mg and metformin XR 1,000 mg
.
OBJECTIVES The aim of this study was to compare the pharmacokinetic (PK) characteristics of evogliptin and metformin following… 
Review
2016
Review
2016
Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel DPP-IV inhibitor , evogliptin ( DA-1229 )
Evogliptin is a novel potent and selective dipeptidyl peptidase-IV (DPP-IV) inhibitor. This study aimed to evaluate the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)